Breaking News

Thermo Fisher Showcases Expanded Biopharma Services at CPHI Milan

Launches Accelerator Drug Development, 360° CDMO and CRO Services.

By: Kristin Brooks

Managing Editor, Contract Pharma

Thermo Fisher Scientific has launched its Accelerator Drug Development, 360° CDMO and CRO Services.
 
Accelerator Drug Development provides a customizable suite of manufacturing, clinical research and clinical supply chain services, including small molecule, biologics and cell and gene therapies, supporting customers at preclinical to commercialization.
 
To help accelerate preclinical oral drug development, Thermo Fisher expanded sites in Cincinnati, OH, and Bend, OR, for research and development, manufacturing and testing of oral solid dose drug formulations.
 
The company also has invested in expanding its global clinical trial network, including a new GMP-certified ultra-cold facility in Bleiswijk, Netherlands, label printing solutions and packaging integration in Basel, Switzerland, and expanded clinical trial logistics services in Buenos Aires, Argentina. The company opened an Innovation Lab in Center Valley, PA, to serve as a coworking lab space to create, test and validate new services that address common pain points across clinical trials.
 
For advanced laboratory services and instrumentation across all phases of pharmaceutical development, Thermo Fisher’s PPD clinical research business is expanding its global laboratory services with a new bioanalytical lab in GoCo Health Innovation City in Gothenburg, Sweden.
 
Also, through a partnership with DHL Express, the PPD clinical research business of Thermo Fisher will use DHL Express’ GoGreen Plus service and invest in sustainable aviation fuel to reduce emissions from air transportation. The collaboration aims to reduce greenhouse gas emissions associated with global clinical research air shipping logistics by up to 80%.

“Thermo Fisher is transforming drug development and manufacturing processes to support customers as they move critical programs forward to tackle global health challenges with speed, quality and efficiency,” said Michael Shafer, executive vice president and president, biopharma services, Thermo Fisher Scientific. “We connect the steps between discovery and delivery – from early testing and analytical support to clinical research design to trial conduct, clinical supply chain management, manufacturing and commercial scale-up – and we strive to ensure a seamless transition, mitigate risks and accelerate innovation at every stage.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters